Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

Inclusion Criteria:

* History of histologically documented MM previously enrolled on UARK 98-026 with relapsed or progressive disease after at least one autologous transplant.
* Patient has measurable disease in which to capture response, defined as:
* Serum M-protein level \> 1.0 gm/dl (10.0 g/L) measured by serum protein electrophoresis or immunoglobulin electrophoresis
* Urinary M-protein excretion \> 200 mg/24 hrs
* Bone marrow plasmacytosis of \> 30percent by bone marrow aspirate and/or biopsy
* Serum Free Light Chains (By the Freelite test) \> 10 mg/dL with an abnormal kappa/lambda ration.
* 50percent increase in size of lytic and/or focal lesions or development of new lesions recognized by radiographic studies.
* Performance status of 2 as per SWOG scale, unless PS of 3-4 based solely on bone pain.
* Patients must have a platelet count 50,000/mm3, unless the low platelet count is due to documented (\>30 percent) extensive myeloma infiltration of the bone marrow.
* Patients must have adequate renal function defined as serum creatinine \< 2.5 mg/dl.
* Patients must have adequate hepatic function defined as serum transaminases and direct bilirubin \< 2 x the upper limit of normal.
* Pregnant or nursing women may not participate. Women of childbearing potential must have a negative pregnancy documented within one week of registration. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
* Male or female adults of at least 18 years of age.
* Patients must have signed and IRB-approved written informed consent form and demonstrate willingness to meet follow-up schedule and study procedure obligations
* \> 5 x 106 CD34 cells/kg in storage strongly desired, but not mandated

Exclusion Criteria:

* Not previously enrolled on UARK 98-026.
* Has received salvage therapy after coming off UARK 98-026.
* Evidence of POEMS Syndrome..
* Significant neurotoxicity interfering with ADL.
* Platelet count \< 50,000/mm3
* Clinically significant hepatic dysfunction as noted by bilirubin or AST \>3 times the upper normal limit or clinically significant concurrent hepatitis.
* New York Hospital Association (NYHA) Class III or Class IV heart failure.
* Myocardial infarction within the last 6 months.
* Truly non-secretory MM (no increase in serum free-light chains) in the absence of bone marrow plasmacytosis and MRI-defined focal lesions with CT-FNA-proven MM
* Uncontrolled, active infection requiring IV antibiotics.
* Patients with a history of treatment for clinically significant ventricular cardiac arrhythmias.
* Poorly controlled hypertension, diabetes mellitus, or other serious or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol.
* Pregnant or potential for pregnancy. Women of childbearing potential will have a pregnancy test at screening, and will be required to use a medically approved contraceptive method. Pregnancy testing will be performed prior to administration of each dose of study drug.
* Breast-feeding women may not participate.